Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview of what to expect. Semaglutide is the active ingredient in three medications approved by the U.S. Food ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

The bar chart below compares the rate of NAION ... who either used a weight-loss jab like semaglutide, had undergone bariatric surgery or had no treatment over a 15-year period.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.